⚠ BETA — all market data shown (deals, filings, prices, indices) is demo / illustrative, not live trading data. For evaluation only; verify before acting.
June 16, 2026
The Dispatch

NSE

Glenmark Pharmaceuticals LimitedGLENMARK

GLENMARK₹2,156.7▲ 0.57% today
Nifty Midcap 150

Glenmark Pharmaceuticals is a research-led branded-generics company.

Key productsDermatology, respiratory and oncology generics & specialty; APIs.
GeographyIndia, US, Europe, emerging markets.
CompetitorsCipla, Sun Pharma, Lupin.

AI-generated overview — verify before relying on it.

Net institutional flow

No institutional deals

Institutional buyers

0 in / 0 out

High-impact filings

0 · tilt Neutral

Next corporate action

Interim Dividend - Rs 2.50 Per Share

ex 2025-10-03

Competitive landscape — the read

vs mapped peers
Institutional money is backing CIPLA hardest (+₹1,527.1 Cr net). GLENMARK ranks #3 of 9 on flow (net buying +₹0 Cr). Filing momentum favours SUNPHARMA (+2). News & social buzz is most positive on DRREDDY.
#CompanyInst. flow ₹CrDealsHi-impactFiling mom.BuzzNews
1CIPLA+₹1,527.1 Cr39—+1+1034
2ALKEM+₹103.5 Cr33——-26
3GLENMARKThis+₹0 Cr6————
4DRREDDY+₹0 Cr4——+1432
5SUNPHARMA+₹0 Cr6—+2+929
6TORNTPHARM+₹0 Cr2————
7LUPIN+₹0 Cr4————
8ZYDUSLIFE+₹0 Cr1————
9AUROPHARMA+₹0 Cr2————

Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.

Timeline — GLENMARK day by day

  1. 2026-06-11FilingGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 11, 2026, titlePress Release
  2. 2026-06-09FilingGlenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationInvestor Call
  3. 2025-10-03ActionInterim Dividend - Rs 2.50 Per ShareDividend
  4. 2025-09-15ActionDividend - Rs 2.50 Per ShareDividend
  5. 2025-07-11BulkBUY · ₹328.1 CrGRAVITON RESEARCH CAPITAL LLP
  6. 2025-07-11BulkSELL · ₹328.3 CrGRAVITON RESEARCH CAPITAL LLP
  7. 2025-03-25BlockBUY · ₹39.5 CrINTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.
  8. 2025-03-25BlockSELL · ₹39.5 CrUBS AG
  9. 2025-01-23BlockBUY · ₹101.4 CrUBS AG
  10. 2025-01-23BlockSELL · ₹101.4 CrUBS PRINCIPAL CAPITAL ASIA LIMITED
  11. 2024-09-13ActionDividend - Rs 2.50 Per ShareDividend

Merged from deals, filings, corporate actions and news — newest first. Scope the deal/action portion with the period chips below.

Filings that matter

  • 2
    Press ReleaseNeutral

    a press release dated Jun 11, 2026, titled "Glenmark Launches Winlevi® (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris".

    Source PDF →
  • 3
    Investor CallNeutral

    Investor Presentation

    Source PDF →

Bulk & block deals

1M3M6M1Y2YAll

6 deals · 2025-01-23 → 2025-07-11

DateCounterpartyInvestor typeSideValue
2025-07-11GRAVITON RESEARCH CAPITAL LLPProp / churnBUY₹328.1 Cr
2025-07-11GRAVITON RESEARCH CAPITAL LLPProp / churnSELL₹328.3 Cr
2025-03-25INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.HNI / otherBUY₹39.5 Cr
2025-03-25UBS AGHNI / otherSELL₹39.5 Cr
2025-01-23UBS AGHNI / otherBUY₹101.4 Cr
2025-01-23UBS PRINCIPAL CAPITAL ASIA LIMITEDHNI / otherSELL₹101.4 Cr

6 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.

Results & transcripts

Financial results

None yet.

News & chatter on GLENMARK

RSS News

0

No recent news.

Google News RSS — links open the source.

The Dispatch

0

No articles yet.

Our coverage.

Reddit

0

No Reddit chatter.

r/ posts mentioning the company.

Twitter / X

0

No posts.

Posts mentioning the company.